Epigenetic Profiling and Liquid Biopsy: Perspectives for Personalized Medicine in Meningioma Patients - MIND

Recruiting now

Conditions studied: Meningioma, Meningioma of Brain

In brief

Meningiomas are the most common primary intracranial tumors. Current treatment relies on surgical resection and radiotherapy, but molecular predictors for recurrence are lacking. This study aims to investigate epigenetic features, specifically histone post-translational modifications (PTMs) and DNA methylation, to stratify patients. The study involves a retrospective cohort to define an epigenetic signature and a prospective cohort to validate it in tissues and liquid biopsies (plasma/EVs).

Key facts

Study ID

NCT07282470

Run by

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

People needed

210

Starts

2024-09-25

Expected to finish

2026-03-01

Last updated by the study team

2026-02-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Inclusion Criteria (Retrospective \& Prospective):
• Patient aged 18 years or older.
• First diagnosis of uni-focal meningioma of the convexity.
• Macroscopical total resection (Simpson 1-3).
• (Retrospective only):
• Surgery performed between 2007 and 2016;
• availability of FFPE sample and medical records.

You may not qualify if…

• Genetic syndromes.
• Diffuse Meningeal Meningiomatosis.
• Patients who underwent experimental treatment in neo-adjuvant setting.
• (Prospective only):
• Previous surgical/medical treatment for another meningioma;
• positive oncological history (e.g., breast cancer).

Where it is running

• Fondazione IRCCS Istituto Neurologico Carlo Besta — Milan, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.